Pharmaceutical company valuation presents unique challenges due to the industry’s distinctive characteristics, including lengthy development cycles, intense regulatory scrutiny, and […]

Imagine you’re a pharmaceutical executive tasked with bringing a groundbreaking drug to market. Time’s ticking, budgets are tight, and the

Imagine a chessboard where every move reshapes the game—pawns merge, knights leap into new territories, and kings secure their reign.

Biosimilars, highly similar versions of reference biologics, have the potential to significantly impact population health management initiatives by increasing access

Pharmaceutical companies are increasingly recognizing the limitations of relying on expensive and often delayed third-party analysts for business intelligence. This

The advent of biosimilars has significantly altered the dynamics of the generic drug industry in Europe. Biosimilars are biological products

The pharmaceutical industry is a complex and competitive landscape, especially after the approval of an Abbreviated New Drug Application (ANDA).

The global generic drug market is expected to grow from $435.3 billion in 2023 to $655.8 billion by 2028, at

The pharmaceutical industry is undergoing a significant shift towards digital transformation, and generic drug development is no exception. This transformation